title: In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody.
abstract: A new single-chain fragment variable (scFv) to TRAIL-R2 receptor produced as minibody (MB2.23) was characterized for anti-lymphoma activity in vivo. For this purpose, a disseminated lymphoma model was generated by intraperitoneal inoculation of BJAB cells in severe combined immunodeficiency mice. Two weekly injections with MB2.23 (10 mg/kg) were able to significantly increase the median survival time of lymphoma-bearing animals with respect to the vehicle-treated control mice, providing a rationale for further investigating the use of MB2.23 in anticancer therapy.
authors: Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy. giorgio.zauli@unife.it
authors: Giorgio
authors: G
authors: Zauli
authors: Federica
authors: F
authors: Corallini
authors: Sonia
authors: S
authors: Zorzet
authors: Vittorio
authors: V
authors: Grill
authors: Roberto
authors: R
authors: Marzari
authors: Paola
authors: P
authors: Secchiero
mesh_terms: D000818:Animals; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007274:Injections, Intraperitoneal; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D016513:Mice, SCID; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000276:immunology*; D057127:Single-Chain Antibodies / Q000008:administration & dosage*; D013997:Time Factors; D023041:Xenograft Model Antitumor Assays
chemical_list: D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D057127:Single-Chain Antibodies; C505639:TNFRSF10B protein, human